Navigation Links
Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
Date:11/11/2009

BOTHELL, Wash., Nov. 11 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, appointed Peter Kingma as senior vice president, effective immediately. In this new role, Mr. Kingma reports to Dave Marver, president and chief executive officer, and oversees the Company's sales, marketing, and service functions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"Our growth plans require that our customer-facing capabilities be outstanding," said Dave Marver, Cardiac Science president and chief executive officer. "We will be launching a series of new products in 2010 that leverage our well-known brands, distribution strength, and large customer base. Peter will help us make the most of those launches and build long-term advantage for the Company through our commercial functions. He also has significant global and business management expertise which will help us fully exploit our many opportunities for international expansion."

Mr. Kingma, 52, worked for Siemens from 1985 to 2008 where he held a number of significant leadership roles in the cardiac technology space. He served as Global Vice President-CT Division in Germany, US Vice President and Business Manager-CT Division, and US Vice President and Business Manager-Molecular Imaging Division. He also served as Managing Director of Siemens Medical Solutions in Australia/New Zealand, and in several senior product and business management roles in Southern Africa. Mr. Kingma has lived and worked in the US, Germany, South Africa, and Australia.

In connection with Mr. Kingma's hiring, the compensation committee of the Company's board of directors approved an inducement grant made outside of the Company's 2002 Equity Incentive Plan pursuant to which Mr. Kingma has been awarded, effective as of close of business on November 16, 2009, a 10-year option to purchase 50,000 shares of common stock of the Company at an exercise price equal to the closing price of the common stock on the Nasdaq Stock Market on the date of grant, with 25 percent of the option to vest after one year of service from the date of grant, and the remaining portion of the option to vest at a rate of 1/36th per month for the next three years thereafter.

Mr. Kingma has an Electrical Engineering (LC) from the Cape Peninsula University of Technology in Cape Town, South Africa and executive business training from the London School of Economics and Duke University's Fuqua School of Business.

About Cardiac Science:

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress test treadmills and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, vital signs monitors, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(®), HeartCentrix(®), Powerheart(®), and Quinton(®) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, YouTube at http://www.youtube.com/user/CardiacScience.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's growth strategies and planned new product launches and the resulting impact on operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2008, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For more information,

    Company Contact:                Investor Contact:     Media Contact:
    Mike Matysik                    Matt Clawson          Christopher Gale
    Cardiac Science Corporation     Allen & Caron         EVC Group Inc.
    Senior Vice President and CFO   949.474.4300          646.201.5431
    425.402.2009                    matt@allencaron.com   203.570.4681
                                                          cgale@evcgroup.com
    CSCX-G

    SOURCE Cardiac Science Corporation


    '/>"/>

SOURCE Cardiac Science Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiac Science Announces Third Quarter Results
2. Boston Scientifics Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
3. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
4. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
5. Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference
6. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the United States to Utilize Newly FDA-Cleared CARTO(R) 3 Navigation System
7. Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest
8. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
9. Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
10. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
11. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... their offering. ... research Uterine cancer Drugs Price Analysis and Strategies - 2016, provides drug ... The research answers the following questions: What are ... are they positioned in the Global Uterine cancer market? ...
(Date:2/20/2017)... Feb. 20, 2017   MedPlast, Inc. , ... industry, announced today that it has signed a ... Device Manufacturing Services business.   The acquisition broadens MedPlast,s ... a leading services provider to the world,s largest ... further expand the company,s capabilities in assembly and ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... , ... Clearwave is the leading provider in ... XT-series of touch screen terminals. Both companies will be showcasing their solutions at ... provider Posiflex is helping to bridge the gap between healthcare hardware and software ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):